Robyn Karnauskas

facebook_page
twitter_page

Last quote by Robyn Karnauskas

The real driver of shares over the next 12-18 [months] is uptake of Spinraza, BIIB's new drug for SMA and our proprietary survey suggests upside to estimates. We currently model Spinraza gaining 10% penetration in the US and modest uptake in ex-US and get to $390M sales in 2017 (consensus at $200-$300M).
Feb 07 2017
Robyn Karnauskas has most recently been quoted in an article called Biogen to rally on this next $1 billion blockbuster drug, Citi says. Robyn Karnauskas said, β€œThe real driver of shares over the next 12-18 [months] is uptake of Spinraza, BIIB's new drug for SMA and our proprietary survey suggests upside to estimates. We currently model Spinraza gaining 10% penetration in the US and modest uptake in ex-US and get to $390M sales in 2017 (consensus at $200-$300M)”.
Automatically powered byStoryzy
<
facebook_page
twitter_page
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided